What type of study is this?

This is a Human Clinical Trial study.

What question did this study set out to answer?

The aim is to evaluate the synergistic effects of oncolytic adenovirus and CAR T cell therapy in treating brain tumors.

November 1, 2025Neuro-OncologyOpen Access

View Full Paper

Ask AI

Bookmark

The aim is to evaluate the synergistic effects of oncolytic adenovirus and CAR T cell therapy in treating brain tumors.
Developed an oncolytic adenovirus co-expressing IL-15 and OX40 ligand.
Administered Delta-24-RGDOX-IL15 intratumorally in mouse models of glioma and melanoma.
Assessed immune cell frequency and activation in brain tumor microenvironments.
Delta-24-RGDOX-IL15 reduced microglia and myeloid cell frequency in tumors.
Increased T cell frequency and activation, including CAR T cells, in treated areas.
20% of mice with melanomas showed long-term survival following treatment.

No takes yet. Share an insight, caveat, or question.

Treatment enhances T cell activity and reduces myeloid cells in brain tumors, suggesting improved outcomes with CAR T cells.

Jiang et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark